SCHEMBL15042892

SCHEMBL15042892

CC(C)c1cc2c(ccc3cccc(C(C)C)c32)[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.49
SLC2A1 P11166 1/20 0.49
KCNN2 Q9H2S1 5/20 0.36
KCNN3 Q9UGI6 5/20 0.36
CASR P41180 2/20 0.33
LMNA P02545 3/20 0.32
FAAH O00519 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
GABRA1 P14867 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
PTGS1 P23219 1/20 0.32
SLC6A2 P23975 1/20 0.32
HTR2C P28335 1/20 0.32
GABRB3 P28472 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24371171 0.80 DHFR (0.42) DHFRSLC2A1CASRLMNAFAAH
SCHEMBL15042893 0.78 DHFR (0.41) DHFRSLC2A1CASRLMNAFAAH
SCHEMBL15042833 0.78 KCNN2 (0.38) DHFRSLC2A1KCNN2KCNN3LMNA
SCHEMBL15042907 0.71 DHFR (0.48) DHFRSLC2A1HPGDKIF11HSD17B10
SCHEMBL9170583 0.71 GABRA1 (0.52) KCNN2KCNN3LMNAFAAHCA1
SCHEMBL17811226 0.69 DAO (0.40) KCNN2KCNN3CASRLMNAFAAH
SCHEMBL19737437 0.69 DAO (0.50) DHFRSLC2A1CYP1A2HPGDKIF11
SCHEMBL15042881 0.69 DHFR (0.46) DHFRSLC2A1LMNAKIF11KDM4E
SCHEMBL11665040 0.68 CYP1A2 (0.54) KCNN2KCNN3CYP1A2CYP3A4HPGD
SCHEMBL16380895 0.68 DHFR (0.48) DHFRSLC2A1CYP3A4HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796705-B2 Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases MERCK SHARP & DOHME CORP. (US) 2017-10-24 US disclosed
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
US-20130156731-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS SCHERING CORPORATION 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130156731-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS HAVCR2, ELOC, ZC3HAV1 DHFR 69/4885SLC2A1 4331/4885KCNN2 4772/4885
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES ZC3HAV1, HAVCR2, ZC3HAV1L DHFR 284/4885SLC2A1 4753/4885KCNN2 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.